Scilex Holding Co. Enters Material Definitive Agreement
Ticker: SCLXW · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1820190
| Field | Detail |
|---|---|
| Company | Scilex Holding Co (SCLXW) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $11.50, $6,250,000, $1.11 million, $25 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
TL;DR
Scilex signed a big deal, details TBD.
AI Summary
Scilex Holding Co. announced on January 2, 2025, that it entered into a material definitive agreement. The filing does not provide specific details about the agreement, its terms, or any associated dollar amounts.
Why It Matters
The entry into a material definitive agreement is a significant event that could impact the company's future operations, financial performance, and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Scilex Holding Co. (company) — Registrant
- January 2, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Scilex Holding Co.?
The filing does not specify the nature of the material definitive agreement.
When did Scilex Holding Co. enter into this material definitive agreement?
Scilex Holding Co. entered into the material definitive agreement on January 2, 2025.
Are there any financial terms or dollar amounts associated with this agreement disclosed in the filing?
No, the filing does not disclose any specific financial terms or dollar amounts related to the agreement.
What is the SEC form type filed by Scilex Holding Co. on January 3, 2025?
The SEC form type filed is a Form 8-K, a Current Report.
What is the primary business of Scilex Holding Co. according to the filing?
According to the filing, Scilex Holding Co. is in the business of Biological Products (No Diagnostic Substances).
Filing Stats: 1,482 words · 6 min read · ~5 pages · Grade level 15.7 · Accepted 2025-01-03 06:06:02
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share SCLX The Nasdaq Stock Mar
- $11.50 — mon stock, each at an exercise price of $11.50 per share SCLXW The Nasdaq Stock Ma
- $6,250,000 — (as defined in the Tranche B Notes) of $6,250,000 per fiscal quarter at a redemption pric
- $1.11 million — Sheet, the Company paid an aggregate of $1.11 million in respect of a portion of the First Am
- $25 m — al installment payment of approximately $25 million, together with accrued interest,
Filing Documents
- d894156d8k.htm (8-K) — 35KB
- d894156dex101.htm (EX-10.1) — 47KB
- d894156dex102.htm (EX-10.2) — 49KB
- d894156dex103.htm (EX-10.3) — 46KB
- 0001193125-25-000984.txt ( ) — 381KB
- sclxw-20250102.xsd (EX-101.SCH) — 4KB
- sclxw-20250102_def.xml (EX-101.DEF) — 14KB
- sclxw-20250102_lab.xml (EX-101.LAB) — 23KB
- sclxw-20250102_pre.xml (EX-101.PRE) — 15KB
- d894156d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Deferral and Consent under Tranche B Senior Secured Convertible Note, dated January 2, 2025, by and among Scilex Holding Company, Nomis Bay Ltd, BPY Limited, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC. 10.2 Deferral and Consent under Tranche B Senior Secured Convertible Note, dated January 2, 2025, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC. 10.3 Deferral and Consent under Tranche B Senior Secured Convertible Note, dated January 2, 2025, by and among Scilex Holding Company, 3i, LP, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCILEX HOLDING COMPANY By: /s/ Jaisim Shah Name: Jaisim Shah Title: Chief Executive Officer & President Date: January 3, 2025 4